Cellcentric's inobrodib, a novel drug with a distinct mechanism of action, shows promise in treating various hematological malignancies, as revealed in a recent publication in Cancer Cell.
The World Health Organization recently endorsed an economical malaria vaccine with a 75% effectiveness rate, which costs less than half of the initial vaccine (RTS,S/AS01) created two years ago. The new vaccine, R21/Matrix-M, developed by the University of Oxford and the Serum Institute of India, marks a significant milestone after decades of scientific research.
Antibiotic resistance among microbial pathogens has increased significantly, and the WHO recognizes this to be a major threat to human health. The following figure projects the estimated number of patient deaths due to antimicrobial resistance every year by 2050:
